Lana Pine

A study in the European Journal of Medical Research revealed that higher maternal study satisfaction, older maternal age, and paternal participation were linked to better compliance in visits for children at risk of type 1 diabetes.

The FDA has approved abatacept (Orencia) for patients aged ≥2 years with active psoriatic arthritis (PsA), a condition causing joint damage in pediatric patients, offering a new treatment option for juvenile PsA, benefiting young patients, caregivers, and healthcare professionals.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

Clinical outcomes of lab values were not statistically different in changes from baseline to 12 months between children with inflammatory bowel disease initiated on the TNF originator or biosimilar.

A cross-sectional, case-controlled cohort study evaluated the cardiorespiratory and neuromuscular fitness of Finnish patients with JIA and healthy controls.

Results of a recent review showed that adalimumab, etanercept, golimumab, and infliximab are effective and well-tolerated treatments options for patients with juvenile idiopathic arthritis.